Strathprints Home | Open Access | Browse | Search | User area | Copyright | Help | Library Home | SUPrimo

Bacteriophage therapy - cooked goose or Phoenix rising?

Mattey, M. and Spencer, J. (2008) Bacteriophage therapy - cooked goose or Phoenix rising? Current Opinion in Biotechnology, 19 (6). pp. 608-612. ISSN 0958-1669

[img] Microsoft Word - Draft Version
Download (70Kb)

    Abstract

    Recent animal and human trials of bacteriophage therapy have demonstrated its potential to alleviate bacterial diseases, both in internal and in external applications. The regulatory requirements are becoming clearer as more examples are presented. A core of GLP (Good Laboratory Practice) studies will be needed to validate safety and clinical trials to validate efficacy. GMP (Good Manufacturing Practice) production requirements and quality issues will mean that comparable costs to the production of conventional antibiotics should be anticipated. The definition of the 'active substance' will be central to the success of bacteriophage therapy to ensure that the variety and evolutionary potential of bacteriophages are exploited.

    Item type: Article
    ID code: 19355
    Keywords: bacteriophage therapy, animal, human trials, Virology
    Subjects: Science > Microbiology > Virology
    Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
    Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences > Bioscience
    Related URLs:
      Depositing user: Strathprints Administrator
      Date Deposited: 02 Jun 2010 11:26
      Last modified: 04 Oct 2012 13:07
      URI: http://strathprints.strath.ac.uk/id/eprint/19355

      Actions (login required)

      View Item

      Fulltext Downloads: